<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ketendo</journal-id><journal-title-group><journal-title xml:lang="ru">Клиническая и экспериментальная тиреоидология</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical and experimental thyroidology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5472</issn><issn pub-type="epub">2310-3787</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/ket10147</article-id><article-id custom-type="elpub" pub-id-type="custom">ketendo-10147</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры литературы</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review of literature</subject></subj-group></article-categories><title-group><article-title>Морфофункциональная характеристика и иммунологическая регуляция функции орбитальных фибробластов при эндокринной офтальмопатии</article-title><trans-title-group xml:lang="en"><trans-title>Morphofunctional characteristics and immunological regulation of the orbital fibroblasts function in endocrine ophthalmopathy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6223-8888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таскина</surname><given-names>Елизавета Сергеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Taskina</surname><given-names>Elizaveta S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Очный аспирант кафедры офтальмологии</p></bio><bio xml:lang="en"><p>Postgraduate student, Department of Ophthalmology</p></bio><email xlink:type="simple">taskins@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8899-5465</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харинцева</surname><given-names>Светлана Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Kharintseva</surname><given-names>Svetlana V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">s.v.19.28@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБОУ ВО Читинская государственная медицинская академия&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;Chita State Medical Academy&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>19</day><month>04</month><year>2019</year></pub-date><volume>14</volume><issue>4</issue><fpage>183</fpage><lpage>191</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Таскина Е.С., Харинцева С.В., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Таскина Е.С., Харинцева С.В.</copyright-holder><copyright-holder xml:lang="en">Taskina E.S., Kharintseva S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cet-endojournals.ru/jour/article/view/10147">https://www.cet-endojournals.ru/jour/article/view/10147</self-uri><abstract><p>Эндокринная офтальмопатия (ЭОП) – это хроническое заболевание, характеризующееся прогрессирующим аутоиммунным воспалением мягких ретробульбарных тканей. В патогенезе инфильтративного процесса и фиброзирования экстраокулярных мышц и/или ретробульбарной клетчатки важное значение имеют орбитальные фибробласты, обладающие уникальными морфофункциональными свойствами. Они в отличие от фибробластов других локализаций имеют не мезодермальное, а нейроэктодермальное происхождение. В обзоре рассматриваются иммунологические аспекты регулирования функции данных клеток в разные фазы активности заболевания. Межклеточное взаимодействие с Т-лимфоцитами (CD40–CD154) приводит к активации орбитальных фибробластов с усилением экспрессии патологических рецепторов к тиреотропному гормону, а также продукции компонентов межклеточного матрикса, молекул адгезии, ростовых факторов, цитокинов и простагландинов. Дана подробная морфофункциональная характеристика отдельных субпопуляций фибробластов орбиты, рассмотрены механизмы регуляции их трансдифференцировки в адипоциты и миофибробласты. Представлен анализ литературных данных по влиянию T-хелперов 17 типа на функциональную активность Thy1+/Thy1- (CD90+/CD90-) орбитальных фибробластов. Отмечена важность дальнейшего изучения особенностей фибробластов орбиты при ЭОП и их межклеточного взаимодействия с различными иммунными клетками, что, возможно, сможет раскрыть новые патогенетические механизмы изучаемой патологии.</p></abstract><trans-abstract xml:lang="en"><p>Endocrine ophthalmopathy (EOP) is a chronic disease characterized by progressive autoimmune inflammation of the soft retrobulbar tissues in thyroid dysfunction. The orbital fibroblasts with their unique morphofunctional properties are very important in the pathogenesis of the infiltrative process and fibrosis of the extraocular muscles and/or retrobulbar tissue. They, unlike other localization fibroblasts, have not mesodermal, but neuro-ectodermal origin. The review acquaints with the immunological aspects of the regulation of these cells in different activity phases of disease. Intercellular interaction with T-lymphocytes (CD40-CD154) leads to orbital fibroblasts activation with increased expression of pathological receptors for thyroid-stimulating hormone, as well as production of intercellular matrix components, adhesion molecules, growth factors, cytokines and prostaglandins. Detailed morphofunctional characteristics of the orbit fibroblast subpopulations and mechanisms regulating their transdifferentiation into adipocytes and myofibroblasts are given. The analysis of literature data on the effect of T-helper type 17 on the functional activity of Thy1+/Thy1- (CD90+/CD90-) orbital fibroblasts is presented. The importance of the further study of the orbital fibroblasts characteristics in EOP and their intercellular interaction with various immune cells was noted, which may be able to uncover new pathogenetic mechanisms of this pathology.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндокринная офтальмопатия</kwd><kwd>патогенез</kwd><kwd>орбитальные фибробласты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Graves’ ophthalmopathy</kwd><kwd>thyroid eye disease</kwd><kwd>endocrine ophthalmopathy</kwd><kwd>pathogenesis</kwd><kwd>orbital fibroblasts</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Свириденко Н.Ю., и др. Федеральные клинические рекомендации по диагностике и лечению эндокринной офтальмопатии при аутоиммунной патологии щитовидной железы. // Проблемы эндокринологии. – 2015. – Т. 61. – №1. – С. 61-74. [Dedov II, Melnichenko GA, Sviridenko NY, et al. Federal clinical recommendations on diagnostics and treatment of endocrine ophthalmopathy associated with autoimmune thyroid pathology. Problems of endocrinology. 2015;61(1):61-74. (In Russ.)] doi: https://doi.org/10.14341/probl201561161-74.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мельниченко Г.А., Свириденко Н.Ю., и др. Федеральные клинические рекомендации по диагностике и лечению эндокринной офтальмопатии при аутоиммунной патологии щитовидной железы. // Проблемы эндокринологии. – 2015. – Т. 61. – №1. – С. 61-74. [Dedov II, Melnichenko GA, Sviridenko NY, et al. Federal clinical recommendations on diagnostics and treatment of endocrine ophthalmopathy associated with autoimmune thyroid pathology. Problems of endocrinology. 2015;61(1):61-74. (In Russ.)] doi: https://doi.org/10.14341/probl201561161-74.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Петунина Н.А., Трухина Л.В., Мартиросян Н.С. Эндокринная офтальмопатия: современный взгляд. // Проблемы эндокринологии. – 2013. – Т. 58. – №6. – С. 24-32. [Petunina NA, Trukhina LV, Martirosyan NS. Endocrine ophthalmopathy: state-of-the-art approaches. Problems of endocrinology. 2013; 58(6):24-32. (In Russ.)] doi: https://doi.org/10.14341/probl201258624-32.</mixed-citation><mixed-citation xml:lang="en">Петунина Н.А., Трухина Л.В., Мартиросян Н.С. Эндокринная офтальмопатия: современный взгляд. // Проблемы эндокринологии. – 2013. – Т. 58. – №6. – С. 24-32. [Petunina NA, Trukhina LV, Martirosyan NS. Endocrine ophthalmopathy: state-of-the-art approaches. Problems of endocrinology. 2013; 58(6):24-32. (In Russ.)] doi: https://doi.org/10.14341/probl201258624-32.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142-150. doi: https://doi.org/10.1136/bjophthalmol-2015-307399.</mixed-citation><mixed-citation xml:lang="en">Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142-150. doi: https://doi.org/10.1136/bjophthalmol-2015-307399.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bahn RS. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res. 2015;47(10):773-778. doi: https://doi.org/10.1055/s-0035-1555762.</mixed-citation><mixed-citation xml:lang="en">Bahn RS. Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res. 2015;47(10):773-778. doi: https://doi.org/10.1055/s-0035-1555762.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cвириденко Н.Ю., Лиханцева В.Г., Беловалова И.М., и др. Антитела к рецептору ТТГ как предикторы тяжести и исходов эндокринной офтальмопатии у пациентов с болезнью Грейвса. // Проблемы эндокринологии. – 2011. – Т. 57. – №2. – С. 23-26. [Sviridenko NYu, Likhantseva VG, Belovalova IM, et al. Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves’ disease. Problems of endocrinology. 2011;57(2):23-26. (In Russ.)] doi: https://doi.org/10.14341/probl201157223-26.</mixed-citation><mixed-citation xml:lang="en">Cвириденко Н.Ю., Лиханцева В.Г., Беловалова И.М., и др. Антитела к рецептору ТТГ как предикторы тяжести и исходов эндокринной офтальмопатии у пациентов с болезнью Грейвса. // Проблемы эндокринологии. – 2011. – Т. 57. – №2. – С. 23-26. [Sviridenko NYu, Likhantseva VG, Belovalova IM, et al. Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves’ disease. Problems of endocrinology. 2011;57(2):23-26. (In Russ.)] doi: https://doi.org/10.14341/probl201157223-26.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83-91. doi: https://doi.org/10.1016/j.exer.2015.02.007.</mixed-citation><mixed-citation xml:lang="en">Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83-91. doi: https://doi.org/10.1016/j.exer.2015.02.007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Fernando R, Lu Y, Atkins SJ, et al. Expression of thyrotropin receptor, thyroglobulin, sodium-iodide symporter, and thyroperoxidase by fibrocytes depends on AIRE. J Clin Endocrinol Metab. 2014;99(7):E1236-1244. doi: https://doi.org/10.1210/jc.2013-4271.</mixed-citation><mixed-citation xml:lang="en">Fernando R, Lu Y, Atkins SJ, et al. Expression of thyrotropin receptor, thyroglobulin, sodium-iodide symporter, and thyroperoxidase by fibrocytes depends on AIRE. J Clin Endocrinol Metab. 2014;99(7):E1236-1244. doi: https://doi.org/10.1210/jc.2013-4271.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177-185. doi: https://doi.org/10.1097/WNO.0000000000000132.</mixed-citation><mixed-citation xml:lang="en">Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177-185. doi: https://doi.org/10.1097/WNO.0000000000000132.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Banga JP, Moshkelgosha S, Berchner-Pfannschmidt U, Eckstein A. Modeling Graves’ orbitopathy in experimental Graves’ disease. Horm Metab Res. 2015;47(10):797-803. doi: https://doi.org/10.1055/s-0035-1555956.</mixed-citation><mixed-citation xml:lang="en">Banga JP, Moshkelgosha S, Berchner-Pfannschmidt U, Eckstein A. Modeling Graves’ orbitopathy in experimental Graves’ disease. Horm Metab Res. 2015;47(10):797-803. doi: https://doi.org/10.1055/s-0035-1555956.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rapoport B, Aliesky HA, Chen CR, McLachlan SM. Evidence that TSH receptor A-subunit multimers, not monomers, drive antibody affinity maturation in Graves’ disease. J Clin Endocrinol Metab. 2015;100(6):E871-875. doi: https://doi.org/10.1210/jc.2015-1528.</mixed-citation><mixed-citation xml:lang="en">Rapoport B, Aliesky HA, Chen CR, McLachlan SM. Evidence that TSH receptor A-subunit multimers, not monomers, drive antibody affinity maturation in Graves’ disease. J Clin Endocrinol Metab. 2015;100(6):E871-875. doi: https://doi.org/10.1210/jc.2015-1528.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kleinau G, Neumann S, Gruters A, et al. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev. 2013;34(5):691-724. doi: https://doi.org/10.1210/er.2012-1072.</mixed-citation><mixed-citation xml:lang="en">Kleinau G, Neumann S, Gruters A, et al. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev. 2013;34(5):691-724. doi: https://doi.org/10.1210/er.2012-1072.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Naik VM, Naik MN, Goldberg RA, et al. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol. 2010;55(3):215-226. doi: https://doi.org/10.1016/j.survophthal.2009.06.009.</mixed-citation><mixed-citation xml:lang="en">Naik VM, Naik MN, Goldberg RA, et al. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol. 2010;55(3):215-226. doi: https://doi.org/10.1016/j.survophthal.2009.06.009.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kotwal A, Stan M. Thyrotropin receptor antibodies – an overview. Ophthalmic Plast Reconstr Surg. 2018;34(4SSuppl1):S20-S27. doi: https://doi.org/10.1097/IOP.0000000000001052.</mixed-citation><mixed-citation xml:lang="en">Kotwal A, Stan M. Thyrotropin receptor antibodies – an overview. Ophthalmic Plast Reconstr Surg. 2018;34(4SSuppl1):S20-S27. doi: https://doi.org/10.1097/IOP.0000000000001052.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lin TY, Li N, Yeh MW, et al. Prognostic indicators for the development of strabismus among patients with Graves’ ophthalmopathy. J Clin Transl Endocrinol. 2017;9:38-40. doi: https://doi.org/10.1016/j.jcte.2017.06.005.</mixed-citation><mixed-citation xml:lang="en">Lin TY, Li N, Yeh MW, et al. Prognostic indicators for the development of strabismus among patients with Graves’ ophthalmopathy. J Clin Transl Endocrinol. 2017;9:38-40. doi: https://doi.org/10.1016/j.jcte.2017.06.005.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Smith TJ. TSHR as a therapeutic target in Graves’ disease. Expert Opin Ther Targets. 2017;21(4):427-432. doi: https://doi.org/10.1080/14728222.2017.1288215.</mixed-citation><mixed-citation xml:lang="en">Smith TJ. TSHR as a therapeutic target in Graves’ disease. Expert Opin Ther Targets. 2017;21(4):427-432. doi: https://doi.org/10.1080/14728222.2017.1288215.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H, Zhu LS, Cheng JW, et al. CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(4):573-582. doi: https://doi.org/10.1007/s00417-014-2902-1.</mixed-citation><mixed-citation xml:lang="en">Wang H, Zhu LS, Cheng JW, et al. CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(4):573-582. doi: https://doi.org/10.1007/s00417-014-2902-1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Feldon SE, Park DJ, O’Loughlin CW, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci. 2005;46(11):3913-3921. doi: https://doi.org/10.1167/iovs.05-0605.</mixed-citation><mixed-citation xml:lang="en">Feldon SE, Park DJ, O’Loughlin CW, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci. 2005;46(11):3913-3921. doi: https://doi.org/10.1167/iovs.05-0605.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1735-1748. doi: https://doi.org/10.1167/iovs.14-14002.</mixed-citation><mixed-citation xml:lang="en">Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1735-1748. doi: https://doi.org/10.1167/iovs.14-14002.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Харинцев В.В., Серебрякова О.В., Серкин Д.М., и др. Роль некоторых про- и противовоспалительных цитокинов в течении эндокринной офтальмопатии. // Забайкальский медицинский вестник. – 2016. – №2. – С. 33-40. [Kharintsev VV, Serebryakova OV, Serkin DM, et al. The role of some pro-inflammatory and anti-inflammatory cytokines in the development of endocrine ophthalmopathy. Zabaykal’skiy meditsinskiy vestnik. 2016;(2):33-40. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Харинцев В.В., Серебрякова О.В., Серкин Д.М., и др. Роль некоторых про- и противовоспалительных цитокинов в течении эндокринной офтальмопатии. // Забайкальский медицинский вестник. – 2016. – №2. – С. 33-40. [Kharintsev VV, Serebryakova OV, Serkin DM, et al. The role of some pro-inflammatory and anti-inflammatory cytokines in the development of endocrine ophthalmopathy. Zabaykal’skiy meditsinskiy vestnik. 2016;(2):33-40. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gillespie EF, Raychaudhuri N, Papageorgiou KI, et al. Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-kappaB. Invest Ophthalmol Vis Sci. 2012;53(12):7746-7753. doi: https://doi.org/10.1167/iovs.12-9861.</mixed-citation><mixed-citation xml:lang="en">Gillespie EF, Raychaudhuri N, Papageorgiou KI, et al. Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-kappaB. Invest Ophthalmol Vis Sci. 2012;53(12):7746-7753. doi: https://doi.org/10.1167/iovs.12-9861.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89-95. doi: https://doi.org/10.3109/07435800.2011.635622.</mixed-citation><mixed-citation xml:lang="en">Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89-95. doi: https://doi.org/10.3109/07435800.2011.635622.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. The effects of tumour necrosis factor-alpha and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis. Eur J Endocrinol. 2006;155(3):395-403. doi: https://doi.org/10.1530/eje.1.02242.</mixed-citation><mixed-citation xml:lang="en">Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. The effects of tumour necrosis factor-alpha and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis. Eur J Endocrinol. 2006;155(3):395-403. doi: https://doi.org/10.1530/eje.1.02242.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology. 2006;147(1):13-19. doi: https://doi.org/10.1210/en.2005-1018.</mixed-citation><mixed-citation xml:lang="en">Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology. 2006;147(1):13-19. doi: https://doi.org/10.1210/en.2005-1018.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94(5):1803-1809. doi: https://doi.org/10.1210/jc.2008-2450.</mixed-citation><mixed-citation xml:lang="en">Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94(5):1803-1809. doi: https://doi.org/10.1210/jc.2008-2450.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Qiao Q, Liu M, et al. IL-17 promotes scar formation by inducing macrophage infiltration. Am J Pathol. 2018;188(7): 1693-1702. doi: https://doi.org/10.1016/j.ajpath.2018.04.005.</mixed-citation><mixed-citation xml:lang="en">Zhang J, Qiao Q, Liu M, et al. IL-17 promotes scar formation by inducing macrophage infiltration. Am J Pathol. 2018;188(7): 1693-1702. doi: https://doi.org/10.1016/j.ajpath.2018.04.005.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Li H, Fitchett C, Kozdon K, et al. Independent adipogenic and contractile properties of fibroblasts in Graves’ orbitopathy: an in vitro model for the evaluation of treatments. PLoS One. 2014; 9(4):e95586. doi: https://doi.org/10.1371/journal.pone.0095586.</mixed-citation><mixed-citation xml:lang="en">Li H, Fitchett C, Kozdon K, et al. Independent adipogenic and contractile properties of fibroblasts in Graves’ orbitopathy: an in vitro model for the evaluation of treatments. PLoS One. 2014; 9(4):e95586. doi: https://doi.org/10.1371/journal.pone.0095586.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kozdon K, Fitchett C, Rose GE, et al. Mesenchymal stem cell-like properties of orbital fibroblasts in Graves’ orbitopathy. Invest Ophthalmol Vis Sci. 2015;56(10):5743-5750. doi: https://doi.org/10.1167/iovs.15-16580.</mixed-citation><mixed-citation xml:lang="en">Kozdon K, Fitchett C, Rose GE, et al. Mesenchymal stem cell-like properties of orbital fibroblasts in Graves’ orbitopathy. Invest Ophthalmol Vis Sci. 2015;56(10):5743-5750. doi: https://doi.org/10.1167/iovs.15-16580.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017; 60:44-65. doi: https://doi.org/10.1016/j.preteyeres.2017.08.001.</mixed-citation><mixed-citation xml:lang="en">Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017; 60:44-65. doi: https://doi.org/10.1016/j.preteyeres.2017.08.001.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Aono Y, Kishi M, Yokota Y, et al. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014;51(6):793-801. doi: https://doi.org/10.1165/rcmb.2013-0455OC.</mixed-citation><mixed-citation xml:lang="en">Aono Y, Kishi M, Yokota Y, et al. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014;51(6):793-801. doi: https://doi.org/10.1165/rcmb.2013-0455OC.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95(1):430-438. doi: https://doi.org/10.1210/jc.2009-1614.</mixed-citation><mixed-citation xml:lang="en">Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95(1):430-438. doi: https://doi.org/10.1210/jc.2009-1614.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wu T, Mester T, Gupta S, et al. Thyrotropin and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2016;26(12): 1768-1777. doi: https://doi.org/10.1089/thy.2016.0243.</mixed-citation><mixed-citation xml:lang="en">Wu T, Mester T, Gupta S, et al. Thyrotropin and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2016;26(12): 1768-1777. doi: https://doi.org/10.1089/thy.2016.0243.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cherng S, Young J, Ma H. Alpha-smooth muscle actin (α-SMA). J Am Sci. 2008;4(4):7-9.</mixed-citation><mixed-citation xml:lang="en">Cherng S, Young J, Ma H. Alpha-smooth muscle actin (α-SMA). J Am Sci. 2008;4(4):7-9.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Krieger CC, Gershengorn MC. A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves’ disease orbital cells. Endocrinology. 2014;155(2):627-634. doi: https://doi.org/10.1210/en.2013-1890.</mixed-citation><mixed-citation xml:lang="en">Krieger CC, Gershengorn MC. A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves’ disease orbital cells. Endocrinology. 2014;155(2):627-634. doi: https://doi.org/10.1210/en.2013-1890.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9-26. doi: https://doi.org/10.1159/000443828.</mixed-citation><mixed-citation xml:lang="en">Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9-26. doi: https://doi.org/10.1159/000443828.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Krieger CC, Neumann S, Place RF, et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab. 2015;100(3):1071-1077. doi: https://doi.org/10.1210/jc.2014-3566.</mixed-citation><mixed-citation xml:lang="en">Krieger CC, Neumann S, Place RF, et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab. 2015;100(3):1071-1077. doi: https://doi.org/10.1210/jc.2014-3566.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2012;97(3):E400-408. doi: https://doi.org/10.1210/jc.2011-2697.</mixed-citation><mixed-citation xml:lang="en">van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2012;97(3):E400-408. doi: https://doi.org/10.1210/jc.2011-2697.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Fanale D, Amodeo V, Caruso S. The interplay between metabolism, PPAR signaling pathway, and cancer. PPAR Res. 2017;2017:1830626. doi: https://doi.org/10.1155/2017/1830626.</mixed-citation><mixed-citation xml:lang="en">Fanale D, Amodeo V, Caruso S. The interplay between metabolism, PPAR signaling pathway, and cancer. PPAR Res. 2017;2017:1830626. doi: https://doi.org/10.1155/2017/1830626.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutr J. 2014;13:17. doi: https://doi.org/10.1186/1475-2891-13-17.</mixed-citation><mixed-citation xml:lang="en">Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review. Nutr J. 2014;13:17. doi: https://doi.org/10.1186/1475-2891-13-17.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Mazumder M, Ponnan P, Das U, et al. Investigations on binding pattern of kinase inhibitors with PPARγ: molecular docking, molecular dynamic simulations, and free energy calculation studies. PPAR Res. 2017;2017:1-11. doi: https://doi.org/10.1155/2017/6397836.</mixed-citation><mixed-citation xml:lang="en">Mazumder M, Ponnan P, Das U, et al. Investigations on binding pattern of kinase inhibitors with PPARγ: molecular docking, molecular dynamic simulations, and free energy calculation studies. PPAR Res. 2017;2017:1-11. doi: https://doi.org/10.1155/2017/6397836.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Kajita K, Mori I, Kitada Y, et al. Small proliferative adipocytes: identification of proliferative cells expressing adipocyte markers [Review]. Endocr J. 2013;60(8):931-939. doi: https://doi.org/10.1507/endocrj.EJ13-0141.</mixed-citation><mixed-citation xml:lang="en">Kajita K, Mori I, Kitada Y, et al. Small proliferative adipocytes: identification of proliferative cells expressing adipocyte markers [Review]. Endocr J. 2013;60(8):931-939. doi: https://doi.org/10.1507/endocrj.EJ13-0141.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л., Денисов Л.Н., Станислав М.Л. Интерлейкин 17 – новая мишень для антицитокиновой терапии иммуновоспалительных ревматических заболеваний. // Прогресс в ревматологии в 21 веке. – 2013. – Т. 51. – №5. – С. 545-552. [Nasonov EL, Denisov LN, Stanislav ML. Interleukin-17 is a new target for anti-cytokine therapy of immune inflammatory rheumatic diseases. Science-practical rheumatology. 2013;51(5):545-552. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Насонов Е.Л., Денисов Л.Н., Станислав М.Л. Интерлейкин 17 – новая мишень для антицитокиновой терапии иммуновоспалительных ревматических заболеваний. // Прогресс в ревматологии в 21 веке. – 2013. – Т. 51. – №5. – С. 545-552. [Nasonov EL, Denisov LN, Stanislav ML. Interleukin-17 is a new target for anti-cytokine therapy of immune inflammatory rheumatic diseases. Science-practical rheumatology. 2013;51(5):545-552. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013;2013:968549. doi: https://doi.org/10.1155/2013/968549.</mixed-citation><mixed-citation xml:lang="en">Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013;2013:968549. doi: https://doi.org/10.1155/2013/968549.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Shen J, Li Z, Li W, et al. Th1, Th2, and Th17 cytokine involvement in thyroid associated ophthalmopathy. Dis Markers. 2015;2015:609593. doi: https://doi.org/10.1155/2015/609593.</mixed-citation><mixed-citation xml:lang="en">Shen J, Li Z, Li W, et al. Th1, Th2, and Th17 cytokine involvement in thyroid associated ophthalmopathy. Dis Markers. 2015;2015:609593. doi: https://doi.org/10.1155/2015/609593.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Hirota K, Hashimoto M, Ito Y, et al. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis. Immunity. 2018;48(6):1220-1232 e1225. doi: https://doi.org/10.1016/j.immuni.2018.04.009.</mixed-citation><mixed-citation xml:lang="en">Hirota K, Hashimoto M, Ito Y, et al. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis. Immunity. 2018;48(6):1220-1232 e1225. doi: https://doi.org/10.1016/j.immuni.2018.04.009.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Qian Y, Kang Z, Liu C, Li X. IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol. 2010;7(5):328-333. doi: https://doi.org/10.1038/cmi.2010.27.</mixed-citation><mixed-citation xml:lang="en">Qian Y, Kang Z, Liu C, Li X. IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol. 2010;7(5):328-333. doi: https://doi.org/10.1038/cmi.2010.27.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Huang H, Kim HJ, Chang EJ, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ. 2009;16(10): 1332-1343. doi: https://doi.org/10.1038/cdd.2009.74.</mixed-citation><mixed-citation xml:lang="en">Huang H, Kim HJ, Chang EJ, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ. 2009;16(10): 1332-1343. doi: https://doi.org/10.1038/cdd.2009.74.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Moran EM, Mullan R, McCormick J, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, oncostatin M and response to biologic therapies. Arthritis Res Ther. 2009; 11(4):R113. doi: https://doi.org/10.1186/ar2772.</mixed-citation><mixed-citation xml:lang="en">Moran EM, Mullan R, McCormick J, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, oncostatin M and response to biologic therapies. Arthritis Res Ther. 2009; 11(4):R113. doi: https://doi.org/10.1186/ar2772.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Wei H, Guan M, Qin Y, et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves’ ophthalmopathy. Endocr J. 2014;61(11):1087-1092. doi: https://doi.org/10.1507/endocrj.EJ14-0246.</mixed-citation><mixed-citation xml:lang="en">Wei H, Guan M, Qin Y, et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves’ ophthalmopathy. Endocr J. 2014;61(11):1087-1092. doi: https://doi.org/10.1507/endocrj.EJ14-0246.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin-17 in Graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1521-1526. doi: https://doi.org/10.1007/s00417-012-2092-7.</mixed-citation><mixed-citation xml:lang="en">Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin-17 in Graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1521-1526. doi: https://doi.org/10.1007/s00417-012-2092-7.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Fang S, Huang Y, Zhong S, et al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in Graves orbitopathy. J Clin Endocrinol Metab. 2017;102(11):4273-4283. doi: https://doi.org/10.1210/jc.2017-01349.</mixed-citation><mixed-citation xml:lang="en">Fang S, Huang Y, Zhong S, et al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in Graves orbitopathy. J Clin Endocrinol Metab. 2017;102(11):4273-4283. doi: https://doi.org/10.1210/jc.2017-01349.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Guo N, Woeller CF, Feldon SE, Phipps RP. Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts. J Biol Chem. 2011;286(21):18856-18867. doi: https://doi.org/10.1074/jbc.M110.179317.</mixed-citation><mixed-citation xml:lang="en">Guo N, Woeller CF, Feldon SE, Phipps RP. Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts. J Biol Chem. 2011;286(21):18856-18867. doi: https://doi.org/10.1074/jbc.M110.179317.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Fang S, Huang Y, Wang S, et al. IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab. 2016;101(8):2955-2965. doi: https://doi.org/10.1210/jc.2016-1882.</mixed-citation><mixed-citation xml:lang="en">Fang S, Huang Y, Wang S, et al. IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab. 2016;101(8):2955-2965. doi: https://doi.org/10.1210/jc.2016-1882.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Paulissen SM, van Hamburg JP, Davelaar N, et al. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J Immunol. 2013;191(3):1364-1372. doi: https://doi.org/10.4049/jimmunol.1300274.</mixed-citation><mixed-citation xml:lang="en">Paulissen SM, van Hamburg JP, Davelaar N, et al. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J Immunol. 2013;191(3):1364-1372. doi: https://doi.org/10.4049/jimmunol.1300274.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Pawlowski P, Reszec J, Eckstein A, et al. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical implications. Mediators Inflamm. 2014;2014:412158. doi: https://doi.org/10.1155/2014/412158.</mixed-citation><mixed-citation xml:lang="en">Pawlowski P, Reszec J, Eckstein A, et al. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical implications. Mediators Inflamm. 2014;2014:412158. doi: https://doi.org/10.1155/2014/412158.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-1040. doi: https://doi.org/10.1038/nm.2807.</mixed-citation><mixed-citation xml:lang="en">Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-1040. doi: https://doi.org/10.1038/nm.2807.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Shin JH, Shin DW, Noh M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem Pharmacol. 2009;77(12):1835-1844. doi: https://doi.org/10.1016/j.bcp.2009.03.008.</mixed-citation><mixed-citation xml:lang="en">Shin JH, Shin DW, Noh M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem Pharmacol. 2009;77(12):1835-1844. doi: https://doi.org/10.1016/j.bcp.2009.03.008.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Pelaez-Garcia A, Barderas R, Batlle R, et al. A proteomic analysis reveals that Snail regulates the expression of the nuclear orphan receptor Nuclear Receptor Subfamily 2 Group F Member 6 (Nr2f6) and interleukin 17 (IL-17) to inhibit adipocyte differentiation. Mol Cell Proteomics.2015;14(2):303-315. doi: https://doi.org/10.1074/mcp.M114.045328.</mixed-citation><mixed-citation xml:lang="en">Pelaez-Garcia A, Barderas R, Batlle R, et al. A proteomic analysis reveals that Snail regulates the expression of the nuclear orphan receptor Nuclear Receptor Subfamily 2 Group F Member 6 (Nr2f6) and interleukin 17 (IL-17) to inhibit adipocyte differentiation. Mol Cell Proteomics.2015;14(2):303-315. doi: https://doi.org/10.1074/mcp.M114.045328.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Jain R, Chen Y, Kanno Y, et al. Interleukin-23-induced transcription factor Blimp-1 promotes pathogenicity of T helper 17 cells. Immunity. 2016;44(1):131-142. doi: https://doi.org/10.1016/j.immuni.2015.11.009.</mixed-citation><mixed-citation xml:lang="en">Jain R, Chen Y, Kanno Y, et al. Interleukin-23-induced transcription factor Blimp-1 promotes pathogenicity of T helper 17 cells. Immunity. 2016;44(1):131-142. doi: https://doi.org/10.1016/j.immuni.2015.11.009.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600. doi: https://doi.org/10.1038/nri3707.</mixed-citation><mixed-citation xml:lang="en">Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600. doi: https://doi.org/10.1038/nri3707.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Бекетова Т.В., Александрова Е.Н., Никонорова Н.О. Интерлейкин 23 у больных системными васкулитами, ассоциированными с антинейтрофильными цитоплазматическими антителами: собственные результаты и обзор литературы. // Научно-практическая ревматология. – 2015. – T. 53. – №5. – C. 493-501. [Beketova TV, Aleksandrova EN, Nikonorova NO. Interleukin-23 in patients with antineutrophil cytoplasmic antibody-associated systemic vasculitides: the authors’ results and a review of literature. Science-practical rheumatology. 2015;53(5): 493-501. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Бекетова Т.В., Александрова Е.Н., Никонорова Н.О. Интерлейкин 23 у больных системными васкулитами, ассоциированными с антинейтрофильными цитоплазматическими антителами: собственные результаты и обзор литературы. // Научно-практическая ревматология. – 2015. – T. 53. – №5. – C. 493-501. [Beketova TV, Aleksandrova EN, Nikonorova NO. Interleukin-23 in patients with antineutrophil cytoplasmic antibody-associated systemic vasculitides: the authors’ results and a review of literature. Science-practical rheumatology. 2015;53(5): 493-501. (In Russ.)]</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
